Adventitious viruses detected in biopharmaceutical bulk harvest samples over a 10 year period

PDA Journal of Pharmaceutical Science and Technology

Volumn 64, Issue 5, 2010, Pages 481-485

  Kerr, Andrew ^a   Nims, Raymond ^a,b  

^a BioReliance   (United States)

^b RMC Pharmaceutical Solutions Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; BIOTECHNOLOGICAL PROCEDURES; CELL CULTURE; CHO CELL; CONFERENCE PAPER; EVALUATION; FEMALE; IN VITRO STUDY; MAMMAL CELL; MOUSE; NONHUMAN; PARVOVIRUS; PHARMACEUTICS; REOVIRUS; SCREENING TEST; VIRAL CONTAMINATION; VIRUS DETECTION; ANIMAL; CELL CULTURE TECHNIQUE; CHO CELL LINE; CRICETULUS; CULTURE MEDIUM; DRUG CONTAMINATION; HUMAN; MAMMALIAN ORTHOREOVIRUS 3; PARVOVIRIDAE; PREVENTION AND CONTROL; VIRUS;

BIOLOGICAL PRODUCT; CULTURE MEDIUM;

ANIMALS; BIOLOGICAL PRODUCTS; CELL CULTURE TECHNIQUES; CHO CELLS; CRICETULUS; CULTURE MEDIA; DRUG CONTAMINATION; HUMANS; MAMMALIAN ORTHOREOVIRUS 3; PARVOVIRUS; VIRUSES;

EID: 78149325644     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Nims, R. Detection of adventitious viruses in biologicals - A rare occurrence. Dev. Biol. (Basel) 2006, 123, 153-164. (Pubitemid 43210364)
2. Genzyme press release, 2009, http://www.genzyme.com/corp/media/GENZ%20PR- 061609.asp.
3. Oehmig, A.; Büttner, M.; Weiland, F.; Werz, W.; Bergemann, K; Pfaff, E. Identification of a calicivirus isolate of unknown origin. J. Gen. Virol. 2003, 84 (10), 2837-2845. (Pubitemid 37220262)
4. US FDA Points to Consider in the Characterization of Cell Lines Used to Produce Biologics, FDA/CDER. 1993.
5. International Conference on Harmonisation ICH Q5A (R1). Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. CPMP/ICH/295/95. October 1997.
6. Shepherd, A. J.; Wilson, N. J.; Smith, K. T. Characterization of endogenous retrovirus in rodent cell lines used for production of biologicals. Biologicals 2003, 31 (4), 251-260.
7. Wiebe, M. E.; Becker, F.; Lazar, R.; May, L.; Casto, B.; Semense, M.; Fautz, C.; Garnick, R.; Miller, C.; Masover, G.; Bergmann, D.; Lubiniecki, A. S. A Multifaceted Approach To Assure That Recombinant tPA Is Free of Adventitious Virus. In Advances in Animal Cell Biology and Technology for Bioprocesses; Spier, R. E., Ed.; Butterworths: London, 1989; pp 68-71.
8. Poiley, J. A.; Nelson, R. E.; Hillesund, T.; Raineri, R. Susceptibility of CHO-K1 cells to infection by eight adventitious viruses and four retroviruses. In Vitro Toxicol. 1991, 4 (1), 1-12.
9. Garnick, R. L. Experience with viral contamination in cell culture. Dev. Biol. Stand. 1996, 88, 49-56.
10. US FDA Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. FDA/CDER 1997.
11. Boose J. A.; Lister, D. C.; Sofer, G. Virus inactivation in the 1990s - and into the 21st Century. Part 6, Inactivation methods grouped by virus. Biopharm Int. 2003, 16 (4), 42-52, 68.
12. Weaver, B. Evaluation of UVC and HTST media treatment for viral risk mitigation in mammalian cell culture processes. PDA Cell Substrates Workshop, Bethesda, MD, 2009. http://www.pda.org/Presentation/PDA-Cell-Substrate-Workshop/ Robert-Weaver.aspx.
13. Schleh, M.; Romanowski, P.; Bhebe, P.; Zhang, L.; Chinniah, S.; Lawrence, B.; Bashiri, H.; Gaduh, A.; Rajurs, V.; Rasmussen, B.; Chuck, A.; Dehghani, H. Susceptibility of mouse minute virus to inactivation by heat in two cell culture media types. Biotechnol. Prog. 2009, 25 (3), 854-860.
14. Nims, R.; Presente, E.; Sofer, G.; Phillips, C.; Chang, A. Adventitious Agents: Concerns and Testing for Biopharmaceuticals. In Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies; Rathore, A., S., Sofer, G., Eds.; CRC Press/Francis Informa: Boca Raton, FL, 2005; pp 143-167.
15. Nims, R. W.; Dusing, SK.; Hsieh, W.-T.; Lovatt, A.; Reid, G. G.; Onions, D.; Milne, E. W. Detection of Cache Valley virus in biologics manufactured in CHO cells. BioPharm Int. 2008, 21 (10), 89-94.
16. Code of Federal Regulations: Animals and Animal Products. Title 9, Part 113.53. US Government Printing Office: Washington, DC, 2003.
17. Kurth, J.; Waldmann, R.; Heith, J.; Mausbach, K.; Burian, R. Efficient inactivation of viruses and mycoplasma in animal sera using UVC irradiation. Dev. Biol. Stand. 1999, 99, 111-118.
18. Gauvin, G.; Nims R. Gamma-irradiation of serum for the inactivation of adventitious contaminants. PDA J. Pharm. Sci. Technol. 2010 (this volume).